Premium
METHISAZONE THERAPY IN PEDIATRIC VACCINIA COMPLICATIONS
Author(s) -
McLean Donald M.
Publication year - 1977
Publication title -
annals of the new york academy of sciences
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1111/j.1749-6632.1977.tb21942.x
Subject(s) - citation , vaccinia , library science , columbia university , medicine , history , media studies , computer science , sociology , biology , biochemistry , gene , recombinant dna
Methisazone 40 mg/kg/day was administered orally to six pediatric and one adult patient who contracted vesicular complications affecting the skin or mucocutaneous junctions 3 to 9 days after antismallpox vaccination, and to one elderly man with myeloid leukemia who developed vaccinia necrosum. Therapy was commenced 2 to 10 days after onset of complications and was administered for 3 days. All patients with skin or mucocutaneous complications showed dramatic clinical responses within one day after commencement of antiviral chemotherapy, and complete recovery occurred within one week. Clinical improvement was noted 4 days after therapy was begun in the case of vaccinia necrosum, and recovery occurred after 3 weeks.